CBC Group and Mubadala Acquire UCB's Mature China Neurology & Allergy Portfolio to Create NeuroGen Pharma

CBC Group, in partnership with Mubadala Investment Company, has completed the US$680 million acquisition of UCB’s mature neurology and allergy product portfolio in China, including brands such as Keppra, Vimpat, Neupro, Zyrtec and Xyzal and a manufacturing site in Zhuhai. The assets have been combined into a new company named NeuroGen Pharma as an anchor platform to build an integrated CNS biopharma business in China and expand capability in neurology and allergy treatments.